CIK: 0001560009 · Show all filings
Period: Q2 2019 (← Previous) (Next →)
Filing Date: Jul 12, 2019
Total Value ($000): $343,186,489 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 4,248,888 | $200,122,625 | 58.3% | $40.26 | -0.7% | Common Stock | H17182108 |
| VCYT | Veracyte, Inc. | 2,410,815 | $68,732,336 | 20.0% | $11.03 | +126.5% | Common Stock | 92337F107 |
| — | Gritstone Oncology, Inc. | 3,102,929 | $34,566,629 | 10.1% | $11140.00 | — | Common Stock | 39868T105 |
| — | Audentes Therapeutics, Inc. | 553,916 | $20,971,260 | 6.1% | $17810.00 | — | Common Stock | 05070R104 |
| OCUL | Ocular Therapeutix, Inc. | 2,215,384 | $9,747,690 | 2.8% | $20.09 | -81.6% | Common Stock | 67576A100 |
| — | CymaBay Therapeutics, Inc. | 543,753 | $3,893,270 | 1.1% | $9871.60 | — | Common Stock | 23257D103 |
| — | Second Sight Medical Products, Inc. | 4,492,975 | $3,597,974 | 1.0% | $1210.00 | — | Common Stock | 81362J100 |
| — | Clovis Oncology, Inc. | 101,855 | $1,514,584 | 0.4% | $56000.00 | — | Common Stock | 189464100 |
| — | OpGen, Inc. | 102,167 | $40,121 | 0.0% | $1780.00 | — | Common Stock | 68373L109 |